Use of an indirect effect model to describe the LDL cholesterol‐lowering effect by statins in hypercholesterolaemic patients
- 27 March 2006
- journal article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 20 (3) , 321-330
Abstract
Statins are the most commonly prescribed agents for the treatment of hypercholesterolaemia. This is due to their efficacy in reducing low-density lipoprotein cholesterol (LDL) level which is the primary goal of the treatment especially for patients with multiple risk factors or with established coronary heart diseases. The purpose of this study was to develop a pharmacokinetic/pharmacodynamic (PK/PD) model that describes the LDL-lowering process in patients with hypercholesterolaemia treated with atorvastatin, fluvastatin or simvastatin. A total of 100 patients were studied retrospectively. They received atorvastatin (n = 57), fluvastatin (n = 26) or simvastatin (n = 17). As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively. A total of 309 LDL levels were measured and the data were analysed by nonmem v. The time course of the LDL-lowering effect of statins was described by an indirect-response model with precursor (LDL synthesis, input rate Kin) and response (circulating LDL, input and output rates K) compartments. The following parameters were estimated: LDL input rate (Kin) 0.14 ± 0.015 g/L/day (mean ± SD); inhibition fraction of Kin (INH) 0.21 ± 0.017; and dose producing 50% increase of LDL removal (D50), 26 ± 7.8, 1.3 ± 0.48 and 15 ± 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively. Gender, bodyweight, age, calories/day, sugar/day, lipids/day, hyperlipidaemia types and waist/hip circumference, renal and hepatic functions had no effect on the pharmacodynamic parameters. The pharmacodynamic parameters for the three statins were accurately estimated. The PK/PD model developed successfully predicted the time course of the LDL-lowering effect of statins.Keywords
This publication has 27 references indexed in Scilit:
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Chemical, pharmacokinetic and pharmacodynamic properties of statins: an updateFundamental & Clinical Pharmacology, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathyHeart, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Current Perspectives on StatinsCirculation, 2000
- New insights into the pharmacodynamic and pharmacokinetic properties of statinsPharmacology & Therapeutics, 1999
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics and Practical Applications of SimvastatinClinical Pharmacokinetics, 1993